Day: June 18, 2024

Annovis Bio Highlights New Alzheimer’s Data at the Alzheimer’s Association International Conference® 2024

Written by Customer Service on . Posted in Public Companies.

MALVERN, Pa., June 18, 2024 (GLOBE NEWSWIRE) — via IBN — Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (AD) and Parkinson’s disease (PD), is pleased to announce that it has been selected to present the data from its latest Alzheimer’s study in an extended 45-minute session at the Alzheimer’s Association International Conference® 2024 (AAIC®). The conference will take place from July 28 to August 1 in Philadelphia, USA, and online. Dr. Cheng Fang, Senior VP of Research & Development at Annovis Bio, along with Kathleen A. Welsh-Bohmer, Ph.D., Professor in Psychiatry and Neurology at Duke University, and Maria L. Maccecchini, Ph.D., Founder, President, CEO of Annovis Bio Inc., will deliver a 45-minute...

Continue reading

Analysis of INPEFA® (Sotagliflozin) Cost-Effectiveness Published in JACC: Heart Failure, the Peer-Reviewed Journal of the American College of Cardiology

Written by Customer Service on . Posted in Public Companies.

New analysis of the pivotal Phase 3 SOLOIST-WHF trial demonstrates INPEFA cost-effectiveness Findings consistent with another study recently published in the Journal of Comparative Effectiveness Research THE WOODLANDS, Texas, June 18, 2024 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the peer-reviewed Journal of the American College of Cardiology: Heart Failure has published a research paper concluding that INPEFA® (sotagliflozin) is cost-effective for people with diabetes and recent worsening heart failure using commonly accepted willingness-to-pay thresholds. “Our research team believes that this study is an important contribution to the economic evaluation of sotagliflozin, a novel SGLT inhibitor, from the perspective of the U.S. healthcare system. Our results demonstrated that in people...

Continue reading

FibroGen to Host Part II of Virtual KOL Investor Event Series to Review FG-3246 Development Program in Metastatic Castration-Resistant Prostate Cancer on June 26, 2024

Written by Customer Service on . Posted in Public Companies.

SAN FRANCISCO, June 18, 2024 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ: FGEN) today announced it will host the second part of its virtual KOL investor event series on Wednesday, June 26, 2024 at 10:00 AM ET. To register, click here. The event will feature Rahul Aggarwal, M.D. (University of California San Francisco), who will discuss the unmet need and evolving treatment landscape for prostate cancer, as well as the clinical development program for FG-3246* (also known as FOR46), a CD46 targeting antibody-drug conjugate (ADC) with first-in-class potential for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The initiation of a Phase 2 monotherapy trial in mCRPC is expected in the second half of 2024. The event will additionally review data from the Phase 1b/2 study evaluating FG-3246 in combination with...

Continue reading

authID and Syntrove Announce OEM Partnership for authID’s Secure Biometric Identity Services

Written by Customer Service on . Posted in Public Companies.

Expands reach of authID’s next-gen biometric identity platform with integration to Syntrove’s risk and fraud technology platform Denver, June 18, 2024 (GLOBE NEWSWIRE) — authID Inc. [Nasdaq: AUID], a leading provider of innovative biometric identity verification and authentication solutions, and Syntrove, a leading consulting and professional services firm specializing in providing risk, data, delivery and technology expertise, today announced they have signed an OEM agreement that will integrate authID’s biometric capabilities in fighting malicious, generative AI-driven fraud, deepfakes, and cyberattacks into the Syntrove offering. Syntrove, whose vision is to be at the forefront of technological and process evolution, will now distribute authID’s next-gen authentication solutions to its portfolio of leading banking, insurance,...

Continue reading

Grifols completes sale of a 20% equity stake in SRAAS and forges strategic alliance with Haier Group

Written by Customer Service on . Posted in Public Companies.

With today’s announcement of the transaction completion, Grifols and Haier Group will work together through Shanghai RAAS (SRAAS) to drive synergies that enhance China’s healthcare system Through a share purchase agreement Grifols has sold a 20% equity stake in SRAAS to Haier Group for RMB 12.5 billion (approximately EUR 1.6 billion) Grifols and SRAAS extend their exclusive albumin distribution agreement over the next 10 years, and SRAAS has the option to prolong it through 2044 Grifols will use all proceeds to comply with its commitment to deleverage BARCELONA, Spain, June 18, 2024 (GLOBE NEWSWIRE) — Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today announced it has completed the sale of a 20% equity stake in Shanghai RAAS (SRAAS) to Haier Group...

Continue reading

DeFi Technologies Subsidiary Valour Inc. Introduces World’s First and Only Yield Bearing Bitcoin (BTC) ETP in Collaboration with Core Foundation, to German Investors on Börse Frankfurt Offering Exposure to Bitcoin with a 5.65% Yield

Written by Customer Service on . Posted in Public Companies.

Launch of Yield-Bearing Bitcoin (BTC) ETP on Börse Frankfurt: Valour Inc. and Core Foundation collaborate to introduce the world’s first yield-bearing Bitcoin (“BTC”) ETP on the Börse Frankfurt Exchange, previously launched on the Nordic Growth Market (“NGM”) with a 1.9% management fee, offering German investors exposure to Bitcoin with a 5.65% yield. Powering Valour Bitcoin Staking (BTC) EUR ETP with Core Blockchain: The Core blockchain network, powered by Bitcoin, forms the foundation for Valour Bitcoin Staking (BTC) EUR ETP (ISIN: CH1213604544), providing Ethereum Virtual Machine (“EVM”) compatibility and the innovative Satoshi Plus consensus mechanism to enhance security and scalability. Simplified Investment with Valour Bitcoin Staking (BTC) EUR ETP: Valour Bitcoin Staking (BTC) EUR ETP streamlines Bitcoin investment by delegating...

Continue reading

Altimmune Announces Oral Presentations of Pemvidutide Clinical Data at Upcoming American Diabetes Association’s Scientific Sessions

Written by Customer Service on . Posted in Public Companies.

GAITHERSBURG, Md., June 18, 2024 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced oral presentations on pemvidutide, an investigational GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and MASH, at the American Diabetes Association’s (ADA) 84th Scientific Sessions, to be held in Orlando, FL from June 21-24, 2024. Details for the oral presentations are as follows: Session Title: Leveling Up Incretin-Based Therapy in Type 2 Diabetes Session Date/Time: Saturday, June 22, 2024, 4:30 PM – 6:00 PM Presentation Title: Effect of Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, on Cardioinflammatory Lipids Presenter: John J. Suschak, Ph.D., Senior Director, Translational Science, Altimmune Presentation Date/Time: Saturday, June...

Continue reading

Zevra Therapeutics Transitions to Orsini as the Specialty Pharmacy Provider for OLPRUVA® (sodium phenylbutyrate), a Treatment for Certain Urea Cycle Disorders

Written by Customer Service on . Posted in Public Companies.

CELEBRATION, Fla. and ELK GROVE VILLAGE, Ill., June 18, 2024 (GLOBE NEWSWIRE) — Orsini Specialty Pharmacy (Orsini), and Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra) today announced that Orsini is now the pharmacy partner for OLPRUVA® (sodium phenylbutyrate) for oral suspension. OLPRUVA® is a prescription medicine used along with certain therapies, including changes in diet, for long-term management of certain adult and pediatric patients with urea cycle disorders (UCDs) involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC) or argininosuccinic acid synthetase (AS). Visit OLPRUVA-Prescribing-Information.pdf (olpruva.com) to view the full Prescribing Information, including Important Safety Information. UCDs are rare genetic disorders that impair the body’s ability to remove excess...

Continue reading

Clubhouse Media Group, Inc. Announces Model and Comedian, Maya Spielman, Joins HoneyDrip.com

Written by Customer Service on . Posted in Public Companies.

LOS ANGELES, June 18, 2024 (GLOBE NEWSWIRE) — Clubhouse Media Group, Inc. (OTC: CMGR) (“Clubhouse Media Group”), a social media firm, today announced that Playboy model and comedian, Maya Spielman, has joined HoneyDrip.com. Spielman has performed stand up comedy in numerous venues, including Flappers Comedy Club and The Comedy Chateau. She has a large following, boasting 215k+ followers on Instagram alone. Honeydrip.com is a digital platform designed and wholly owned by CMGR with a focus on the empowerment of creators. The site allows creators to connect and engage with fans and monetize exclusive content. “The HoneyDrip platform has attracted a vast array of professional creators,” said Alexandra Bolanos, Manager at HoneyDrip.com. “Our team works 24/7 and ensures that fans have access to the most exclusive and high...

Continue reading

BlueRush Announces Proposed Non-Brokered Private Placement

Written by Customer Service on . Posted in Public Companies.

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, June 18, 2024 (GLOBE NEWSWIRE) — BlueRush Inc. (“BlueRush” or the “Company”) ‎‎‎(TSXV:BTV; ‎OTCQB:BTVRF), ‎a personalized video Software as a Service (“SaaS”) company, announced today a proposed non-brokered private placement financing pursuant to which BlueRush proposes to raise gross proceeds of up to $1,020,000 through the issuance of up to 68 units (a “Unit” or “Units”) of the ‎Company at $15,000 per Unit (the “Offering”). Each Unit shall consist of (i) 500,000 common shares of the ‎Company (the “Common Shares”) at a deemed price of $0.02 per Common Share, (ii) 500,000 transferable common share purchase warrants, with each warrant ‎‎entitling the holder thereof to acquire one additional Common Share ‎at a price of $0.05...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.